A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →. With Merck Sharp & Dohme LLC.
Phase
Phase 2
Status
Terminated
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
38actual
Sites
24
Countries
Germany, Italy, Poland +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Study terminated due to inability to recruit the target number of patients. There were no safety and/or efficacy concerns involved in the decision to stop enrollment.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-06-13 | actual | When the study began enrolling |
| Primary completion | 2026-02-02 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-02-02 | actual | The whole study's end, after follow-up |
| First posted | 2023-07-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Melanoma
Interventions
- Drug: encorafenib — also filed as BRAFTOVI
- Drug: binimetinib — also filed as MEKTOVI
- Drug: pembrolizumab — also filed as KEYTRUDA®
- Drug: ipilimumab — also filed as YERVOY
- Drug: nivolumab — also filed as OPDIVO
Primary outcome
what the primary-completion date above is the date OFObjective Response Rate (ORR) is defined as the proportion of participants in each treatment arm with a confirmed best overall response of either Complete Response (CR) or Partial Response (PR), as determined by investigator assessment per RECIST v1.1
measured Time from the date of randomization to the earliest date disease progression, or start of subsequent anticancer therapy, or death due to any cause (assessed up to approximately 48 months).
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed